IShares Genomics Financial Statements From 2010 to 2025
| IDNA Etf | USD 21.95 0.19 0.87% |
Check IShares Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among IShares Genomics' main balance sheet or income statement drivers, such as , as well as many indicators such as . IShares financial statements analysis is a perfect complement when working with IShares Genomics Valuation or Volatility modules.
IShares |
iShares Genomics Immunology ETF Beta Analysis
IShares Genomics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current IShares Genomics Beta | 1.14 |
Most of IShares Genomics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, iShares Genomics Immunology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, iShares Genomics Immunology has a Beta of 1.14. This is much higher than that of the iShares family and significantly higher than that of the Health category. The beta for all United States etfs is notably lower than that of the firm.
About IShares Genomics Financial Statements
IShares Genomics stakeholders use historical fundamental indicators, such as IShares Genomics' revenue or net income, to determine how well the company is positioned to perform in the future. Although IShares Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in IShares Genomics' assets and liabilities are reflected in the revenues and expenses on IShares Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in iShares Genomics Immunology. Please read more on our technical analysis and fundamental analysis pages.
The fund generally will invest at least 80 percent of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. Genomics Immunology is traded on NYSEARCA Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iShares Genomics Imm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IShares Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ishares Genomics Immunology Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Ishares Genomics Immunology Etf:Check out the analysis of IShares Genomics Correlation against competitors. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
The market value of iShares Genomics Imm is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Genomics' value that differs from its market value or its book value, called intrinsic value, which is IShares Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Genomics' market value can be influenced by many factors that don't directly affect IShares Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.